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ARTICLE
Clinical, biochemical, cellular and molecular
characterization of mitochondrial DNA depletion
syndrome due to novel mutations in the MPV17 gene
Johanna Uusimaa1,2,17, Julie Evans3,17, Conrad Smith3, Anna Butterworth4, Kate Craig4, Neil Ashley1,
Chunyan Liao1, Janet Carver1, Alan Diot1, Lorna Macleod1, Iain Hargreaves5, Abdulrahman Al-Hussaini6,
Eissa Faqeih6, Ali Asery6, Mohammed Al Balwi7, Wafaa Eyaid8, Areej Al-Sunaid8, Deirdre Kelly9,
Indra van Mourik9, Sarah Ball10, Joanna Jarvis11, Arundhati Mulay12, Nedim Hadzic13, Marianne Samyn13,
Alastair Baker13, Shamima Rahman14, Helen Stewart15, Andrew AM Morris16, Anneke Seller3, Carl Fratter3,
Robert W Taylor4 and Joanna Poulton*,1
Mitochondrial DNA (mtDNA) depletion syndromes (MDS) are severe autosomal recessive disorders associated with decreased
mtDNA copy number in clinically affected tissues. The hepatocerebral form (mtDNA depletion in liver and brain) has been
associated with mutations in the POLG, PEO1 (Twinkle), DGUOK and MPV17 genes, the latter encoding a mitochondrial inner
membrane protein of unknown function. The aims of this study were to clarify further the clinical, biochemical, cellular and
molecular genetic features associated with MDS due to MPV17 gene mutations. We identified 12 pathogenic mutations in the
MPV17 gene, of which 11 are novel, in 17 patients from 12 families. All patients manifested liver disease. Poor feeding,
hypoglycaemia, raised serum lactate, hypotonia and faltering growth were common presenting features. mtDNA depletion in
liver was demonstrated in all seven cases where liver tissue was available. Mosaic mtDNA depletion was found in primary
fibroblasts by PicoGreen staining. These results confirm that MPV17 mutations are an important cause of hepatocerebral
mtDNA depletion syndrome, and provide the first demonstration of mosaic mtDNA depletion in human MPV17 mutant fibroblast
cultures. We found that a severe clinical phenotype was associated with profound tissue-specific mtDNA depletion in liver,
and, in some cases, mosaic mtDNA depletion in fibroblasts.
European Journal of Human Genetics (2014) 22, 184–191; doi:10.1038/ejhg.2013.112; published online 29 May 2013
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INTRODUCTION
During the last decade, an increasing number of nuclear genetic
defects have been identified causing mitochondrial dysfunction either
through the accumulation of mitochondrial DNA (mtDNA) deletions
(multiple deletions) or through a reduction in mtDNA copy number
causing mtDNA depletion syndromes (MDS), the latter of which are
autosomal recessive diseases characterized by a severe, tissue-specific
decrease of mtDNA copy number. At least 12 nuclear genes have been
found to be involved in mtDNA maintenance, including POLG,
POLG2, PEO1, SLC25A4, TYMP, DGUOK, TK2, SUCLA2, SUCLG1,
MPV17, OPA1 and RRM2B genes.1 MDS are caused by recessive
defects in proteins directly involved in mtDNA replication or
in proteins that affect the availability of deoxyribonucleoside
triphosphates for mtDNA synthesis. Clinical presentations of MDS
include early-onset hepatocerebral disease overlapping with Alpers-
Huttenlocher syndrome (henceforth ‘Alpers’), isolated myopathy,
encephalomyopathy and mitochondrial neurogastrointestinal
encephalomyopathy syndrome. MDS are classified as myopathic,
encephalomyopathic or hepatocerebral forms, of which the latter
group has been associated with mutations in POLG, PEO1 (Twinkle),
DGUOK and MPV17 genes.2
The human MPV17 gene is located on chromosome 2p21-23,
comprising eight exons encoding 176 amino acids. It is expressed in
human pancreas, kidney, muscle, liver, lung, placenta, brain and heart.
MPV17 encodes a mitochondrial inner membrane protein, which has
a so far largely unknown role in mtDNA maintenance. Human
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MPV17 is the orthologue of the mouse kidney disease gene, Mpv17.
Loss of function has been shown to cause hepatocerebral MDS with
oxidative phosphorylation failure and mtDNA depletion both in
affected individuals and inMpv17/ mice.3 To date, MDS caused by
MPV17 mutations has been reported in 32 patients with the clinical
manifestations including early progressive liver failure, neurological
abnormalities, hypoglycaemia and raised blood lactate.4–15 Recently,
MPV17 mutations have also been associated with autosomal recessive
adult-onset neuropathy and leukoencephalopathy with multiple
mtDNA deletions in skeletal muscle.16 Thus, as for POLG, RRM2B
and TK2, MPV17 mutations can lead to recessive MDS or recessive
multiple mtDNA deletion disorders.
The aim of this study was to clarify further the clinical, biochem-
ical, cellular and molecular features associated with MDS due to
MPV17 gene mutations. We report 17 cases from 12 families with 11
novel MPV17 mutations. All the patients presented with early-onset
liver disease but only some patients manifested neurological dysfunc-
tion. Furthermore, we demonstrate that primary fibroblast cultures
from patients with MPV17 mutations may exhibit a mosaic mtDNA
depletion.
SUBJECTS AND METHODS
We studied 70 unrelated probands with suspected hepatocerebral MDS who
had been referred to Mitochondrial Diagnostic Centres at Oxford, Newcastle
or London for clinical assessment, histological, biochemical and/or molecular
genetic analyses. This study was approved and performed under the ethical
guidelines issued by each institution for clinical studies, with written informed
consent obtained for all subjects.
Molecular genetics
Total genomic DNA was isolated from blood leukocytes, skeletal muscle and
liver samples by standard methods. Long-range PCR amplification of 13.8 kb
mtDNAwas undertaken to screen for mtDNA deletions in the available muscle
and liver DNA samples, using primers previously described.17 mtDNA copy
number relative to nDNA levels in muscle and/or liver DNAwas estimated and
compared with age-matched normal controls18,19 by real-time quantitative
PCR as described previously,20 except the nuclear probe was labelled with Vic
at the 50 end and the assays were carried out simultaneously using a PE7500
real-time PCR instrument (Applied Biosystems, Life Technologies, Carlsbad,
CA, USA). mtDNA copy numbero30% compared with age-matched controls
was classed as mtDNA depletion, 30–50% as borderline low, and 450% as
normal. The entire coding and flanking intronic regions of MPV17 were
amplified by PCR from genomic DNA and sequenced by fluorescent dideoxy
sequencing (Applied Biosystems Big Dye Terminator v3.1 kit) and capillary
electrophoresis (Applied Biosystems 3730). Results were compared with
Genbank reference sequences NM_002437.4 and NG_008075.1, and mutations
described in accordance with HGVS nomenclature guidelines. MPV17 exon
copy number (exons 1–8) was assessed by MLPA (kit P089-A1; MRC-Holland,
Amsterdam, The Netherlands) in patients 16 and 17 (family 12) to confirm the
deletion of multiple exons. Where available, parental blood DNA samples were
analysed for the familial mutation(s) by sequencing of the appropriate exon, or
by MLPA for family 12.
Muscle histology, histochemistry and biochemistry
Tissue samples from muscle and liver were obtained according to standard
procedures. Muscle and liver histology and histochemistry were performed by
standard methods. The activities of mitochondrial respiratory chain enzyme
complexes were determined from skeletal muscle and liver biopsy samples and
cultured skin fibroblasts, as previously described.21,22
Characterization of the cellular mtDNA depletion phenotype by
PicoGreen staining of fibroblasts
Cell cultures were analysed using the fluorescent stains PicoGreen (Molecular
Probes, Eugene, OR, USA) (dsDNA intercalator) and tetramethylrhodamine
methylester (TMRM; reflects mitochondrial membrane potential). Staining
with PicoGreen is a simple, semi-quantitative method for visualizing mtDNA
in situ within living cells as described.23 mtDNA nucleoids were further
quantified using the IN Cell 1000 analyser (GE Healthcare Life Science, Little
Chalfont, UK). Control and patients’ fibroblasts were stained with PicoGreen
and 30nM TMRM as above in clear Optimem media (Gibco, Life
Technologies). Raw images were acquired and binarized to quantify mtDNA
nucleoids per cell. Nucleoids were defined as PicoGreen punctae present in the
cytoplasm and colocalizing with mitochondria.
RESULTS
Analysis of the MPV17 gene
We identified pathogenic mutations in the MPV17 gene in 12 out of
70 probands screened representing 17% of our undiagnosed cohort
of children with suspected hepatocerebral MDS. Ten probands
harboured homozygous mutations, and two had compound
heterozygous mutations. A familial homozygous mutation was also
identified in further affected siblings from families 4, 5, 9 and 12,
resulting in a total of 17 patients from 12 families (Table 1). Eleven of
the 12 mutations we identified are previously unpublished, and as such
considered to be novel: c.62T4G (p.Leu21Arg), c.67G4C (p.Ala23-
Pro), c.107A4C (p.Gln36Pro), c.121C4T (p.Arg41Trp), c.130C4T
(p.Gln44*), c.135delA (p.Glu45Aspfs*8), c.191C4G (p.Pro64Arg),
c.278A4C (p.Gln93Pro), c.279þ 1G4T, c.461þ 1G4C and a dele-
tion including exons 3–8 of MPV17 (Figures 1 and 2).
Five of the 11 novel mutations are predicted to be protein
truncating: c.279þ 1G4Tand c.461þ 1G4C alter a consensus splice
site; c.130C4T is a nonsense mutation (p.Gln44*); c.135delA results
in a frameshift (p.Glu45Aspfs*8) and one mutation is a large deletion
of exons 3–8. The remaining six novel mutations are missense
changes, which are scattered throughout the protein (Figure 2), and
alter amino acids, which are highly conserved across vertebrates
(Supplementary Figure 1).
Homozygosity for theMPV17mutation in patients from families 1,
3–5, 7–10 and 12 was confirmed by parental testing, which demon-
strated all parents to be heterozygous carriers. Parental samples were
not available for family 11. For patients 2 (family 2) and 9 (family 6),
at least one parent was found to be a heterozygous carrier in each
case, thereby confirming compound heterozygosity.
Molecular genetic studies on mtDNA from muscle and tissue
samples
Molecular genetic analyses did not reveal any significant large-scale
mtDNA rearrangements in any of the available muscle or liver DNA
samples. mtDNA copy number was compared as previously18,19 with
controls matched for age but not ethnicity. Severe mtDNA depletion
in liver was demonstrated for five out of seven cases (5–14% of
control mtDNA) where liver tissue was available (patients 2, 3, 11, 14
and 16). Patient 9 had clear but less severe mtDNA depletion in liver
(21% of controls), whereas mtDNA copy number was borderline low
(40% of controls) in the remaining case (patient 4). Mean mtDNA
copy number of all seven cases was 16%. In contrast, mtDNA copy
number was highly variable across the six cases where muscle tissue
was available (10–100% of controls, mean 46%; Table 1).
Clinical and laboratory features of patients withMPV17 mutations
The 17 individuals in our cohort came from 12 families, 6 being male
and 11 female, from different ethnic populations including Asian,
Middle-Eastern and Caucasian families. All patients manifested with
liver disease with abnormal liver function tests. Poor feeding,
hypoglycaemia, raised plasma lactate, hypotonia and faltering growth
MPV17 mutations causing mtDNA depletion syndrome
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were common preliminary features. In four cases, the growth failure
was attributed to poor feeding, two poor weight gain in the presence
of adequate food intake and one growth failure. Detailed clinical
summaries for each patient are provided in Supplementary File 1.
Laboratory findings revealed hypoglycaemia, and patients with liver
impairment had raised plasma levels of bilirubin, transaminases, GGT,
ferritin, alpha fetoprotein and coagulopathy. Plasma lactate levels that
were initially raised (ranging from 3mmol/l to 21.4mmol/l; normal
range 0.7–2.1mmol/l) usually decreased, corresponding to an obvious
clinical improvement. CSF lactate values varied from normal to
5.1mmol/l (normal range 1.1–2.2mmol/l). Five of the 17 patients had
at least one normal blood lactate or one normal CSF lactate. Plasma
amino acids were increased including methionine, tyrosine and
arginine (15-fold and 10-fold above the upper limit of the normal
range, respectively), and a 2–3-fold increase of glutamine, alanine,
serine, glycine or threonine.
Age at presentation ranged from birth to 5 years. Five patients (4, 9,
13, 14 and 17) have survived with current ages varying from 5 months
to 11.5 years (mean age 4.4 years). The median age at death was 13
months (range from 3 months to 4.3 years). Two patients (6 and 9)
underwent liver transplantation. Patient 6 received a liver transplant
at the age of 9 months, but died due to neurological and renal
manifestations at the age of 2.5 years. Conversely, patient 9 received a
liver transplant at the age of 3 years and is currently 11.5 years old
manifesting with progressive demyelinating peripheral neuropathy,
hypoparathyroidism and severe growth hormone deficiency. Where
studied, liver ultrasound showed an enlarged echogenic liver (patients
1, 7 and 12), a distended gall bladder with biliary sludge (patients 1
and 8), nodular/heterogeneous liver parenchyma (patients 4, 5 and 8)
and ascites in the abdomen and pelvis (patients 5 and 12). Brain MRI
scans revealed global cerebral and cerebellar atrophy (patient 6), brain
infarction (patients 6 and 7) and white matter changes consistent with
metabolic leucodystrophy in five patients (patients 1, 4, 5, 6 and 10)
from our cohort. Neuropathy was a feature of family 4, with corneal
scarring likely due to sensory deficit, as described in Navajo familial
neurogenic arthropathy.24
Figure 1 Mutations in the MPV17 gene. Schematic representation of the MPV17 gene, comprising eight exons of which exons 2–8 are coding (coding
region coloured in orange); the positions of the 4 a-helical transmembrane spanning domains are indicated by red bars; missense/inframe deletion
mutations are shown above the schematic and truncating/splicing mutations are shown below the schematic; novel mutations are indicated in blue,
previously reported mutations also identified in this study in green and previously reported mutations not identified in this study in black.
Figure 2 Location of missense mutations in the MPV17 protein. Schematic representation of the MPV17 protein, which is localized to the inner
mitochondrial membrane; the 4 a-helical transmembrane spanning domains are indicated by red rectangles, and the number of the first and last amino
acids of each of these domains is annotated in white; novel missense mutations are indicated in blue, previously reported missense mutations also
identified in this study in green and previously reported missense/inframe deletion mutations not identified in this study in grey.
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Histopathological features
The histological assessment of a diagnostic muscle biopsy was
performed in six patients. Histopathological changes varied from
normal findings (patients 2, 4 and 5) to fatty infiltration (patients 7
and 9), to a generalized fibre atrophy with small angular fibres
(patient 16).
Liver histology was available from 13 of the 17 patients. Histo-
pathological features included: fatty infiltration (patients 2, 4, 6, 7, 9,
10, 13, 14 and 16), fibrosis/cirrhosis (patients 2, 4, 5, 10 and 14),
severe panlobular loss of hepatocytes and stromal collapse (patient 3),
giant cell hepatitis with haemorrhagic necrosis (patient 6), non-
specific changes (patient 11), cholestasis (patients 14 and 16), patchy
hepatocellular oncocytosis and single-cell necrosis (patient 15),
abundant mitochondria with mild pleomorphism (patient 9), marked
distension of hepatocytes and few periportal glycogen deposits
(patient 10) and mild iron deposition in Kupffer cells (patient 13).
Biochemical and histochemical analyses
Table 1 Muscle tissue, liver tissue and/or skin fibroblasts were
available for the assessment of mitochondrial respiratory chain
function from 7 out of 12 probands. Respiratory chain analysis in
muscle at or soon after initial clinical presentation suggested a
combined deficiency of respiratory chain complex activities in four
patients (7, 9, 10 and 15), whereas the enzyme activities were normal
in muscle samples from patients 2, 3 and 4 as well as in liver from
patient 4 (who had the highest mtDNA copy number) and fibroblasts
from patient 3. Unfortunately, biochemical analyses of liver from
patients 3, 11 and 15 with mosaic mtDNA depletion in fibroblasts
were not available. Sequential COX-SDH histochemistry revealed a
severe, near-global COX deficiency in the liver from patient 2. Initial
muscle histology at the age of 28 months from patient 9 was within
normal limits, concurrent respiratory enzyme assays showing a
borderline complex I deficiency. A repeat muscle biopsy from patient
9 at 3 years revealed slightly decreased respiratory chain activities of
both complex I and complex IV (cytochrome c oxidase; 82% of
control values). Complex IV activity was 27% of control in the
explanted liver tissue. These findings are also summarized in Table 1.
Characterization of the cellular mtDNA depletion phenotype by
PicoGreen staining of fibroblasts
Fibroblast cultures were available from 8 of the 17 patients in our
cohort. mtDNA was visualized in these cultures using PicoGreen
fluorescence microscopy and the membrane potential-dependent
mitochondrial probe, TMRM. PicoGreen staining provides a quanti-
tative measure of mtDNA content in a cell, and is more sensitive to
small localized depletion than real-time PCR. mtDNA is arranged
into punctate DNA/protein structures, termed nucleoids in vivo,
consisting of several mtDNA genomes complexed to nucleoid
proteins. Mosaic mtDNA depletion was clearly observed in fibroblasts
from fourMPV17 patients (patients 3, 11, 15 and 17; Figures 3c and e
and Supplementary Information 2). In two patients, intermediate
mtDNA depletion was observed with fibroblast mtDNA staining
being generally paler (patients 4 and 8) whereas PicoGreen staining
was normal in fibroblasts from patients 2 and 9. Cells showing the
most marked mtDNA depletion exhibited a decreased mitochondrial
membrane potential following TMRM staining. This was reflected by
real-time PCR (Supplementary Information 2), which showed that
the average mtDNA copy number in the cell lines with mosaic
depletion was 70% (range 35–100%) of expected compared with 89%
(range 43–150%) in the other patient lines (four controls, mean
100%, range 70–136%). Real-time PCR was supported by
quantitation of nucleoid numbers using IN Cell 1000 analyser
(Supplementary Information 2).
DISCUSSION
We have performed clinical, biochemical, immunocytochemical and
molecular genetic studies of 17 patients with MDS associated with
MPV17 mutations, demonstrating a loose relationship between
the clinical phenotype and mutational genotype, with patients with
the most severe mtDNA depletion in liver tending to present and die at
an earlier age. We have also demonstrated a mosaic mtDNA depletion
in fibroblasts from some of the more severely affected patients.
Previously, MPV17 mutations have been reported in 32
patients with the hepatocerebral form of MDS in which the most
common clinical manifestations included early progressive liver failure,
hypoglycaemia and raised plasma lactate concentrations.4–15 Some of
these patients manifested with neuromuscular abnormalities including
hypotonia, nystagmus, encephalopathy, developmental delay/mental
retardation, microcephaly, seizures, myoclonus, myopathy, ataxia and/
or peripheral neuropathy (Navajo neurohepatopathy). White matter
changes and abnormalities within the reticular formation of the lower
brain stem and within the reticulospinal tracts at the cervicocranial
junction on MR imaging have been reported.13,15
Clinical findings and differential diagnoses
All our 17 patients presented with liver disease; other common
features included raised serum lactate concentrations, hypotonia and
faltering growth. Rarer features included endocrine abnormalities
(hypoparathyroidism in patient 9, pituitary dysfunction in patient 12
and hypothyroidism in patient 15), retinal pigmentation (patients 10
and 13), corneal scarring24 (patient 5) and progressive demyelinating
peripheral neuropathy (patients 4 and 9).7,11 In addition, three
patients were found with minor dysmorphic features (patients 12,
15 and 16), which have not been described previously. Thus, the
clinical findings in our cohort of MDS patients with MPV17
mutations are broadly similar to those previously reported.
The infantile phenotypes of hepatocerebral forms of MDS asso-
ciated with mutations in POLG, PEO1 (Twinkle), DGUOK or MPV17
have similarities, presenting with liver failure along with various
neurological and endocrinological manifestations. Significant hypo-
glycaemia, that is glucose levels that are more difficult to maintain
with oral supplementation than would be expected from the degree of
liver failure, was commonly present in patients with MPV17 muta-
tions as previously reported.4 We also observed raised levels of
tyrosine in blood and/or urine in three patients, as can occur in
patients with DGUOK mutations.24 We have also noted a tendency
for the liver failure to precede severe neurological problems, whereas
in our experience the sequence tends to be the other way round in
patients with classical Alpers syndrome due to POLG mutations: in
only 1 out of 24 of our series did liver dysfunction clearly precede
neurological involvement.20 For this reason, patient 6 underwent a
liver transplant at 15 months of age, but died 15 months later,
following neurological and renal deterioration. In summary,
presentations of patients with MPV17 mutations were most like
those of patients with DGUOK-associated MDS, who typically have
neonatal liver failure and hypotonia.25
MPV17 mutations
Twelve different mutations were identified in our cohort of 17
patients (12 probands), including 11 novel mutations (6 missense, 5
truncating) in the MPV17 gene (Figure 1). This adds significantly to
the 21 previously reported mutations.4–16 The seven missense
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mutations (six novel and one previously reported) identified in our
cohort are scattered throughout the protein (Figure 2), with no
significant clustering. This is in contrast to El-Hattab et al,11 who
reported clustering of missense mutations in the region of the
putative protein kinase C phosphorylation site.
The majority of patients in our cohort presented in the first few
weeks of life and died before 2 years of age (although three patients
currently aged 5–14 months are living and so their clinical course
cannot be predicted), and these patients had either truncating or
missense mutations in MPV17 that presumably led to complete loss
of functional protein. However, patients from families 4 and 6
(patients 4, 5, 6 and 9) appear to have a milder disease with better
prognosis. These patients are/were either homozygous or compound
heterozygous for missense mutations, namely p.Arg41Trp, p.Pro64Arg
and p.Pro98Leu, suggesting that these mutant MPV17 proteins retain
some residual function. This is similar to the findings of Karadimas
et al,5 who reported patients homozygous for p.Arg50Gln or
compound heterozygous for p.Gly94Arg and p.Pro98Leu, with a
relatively mild form of hepatocerebral MDS, namely Navajo
neurohepatopathy. It is interesting to note that both p.Arg41Trp
and p.Arg50Gln are located in the same protein loop in the
intermembrane space (Figure 2).
As a result of identifying pathogenic MPV17 mutations, prenatal
diagnosis and/or preimplantation genetic diagnosis is now available to
these 12 families. Indeed, the parents of patient 16 opted to have
amniocentesis and MPV17 analysis in two subsequent pregnancies,
who were accurately identified as an unaffected carrier and an affected
girl (patient 17).
Mitochondrial respiratory chain analyses and mtDNA depletion in
tissue samples
Respiratory chain deficiency and mtDNA depletion are usually present
in the muscle of MDS patients, but not in all patients. In cases with
isolated liver involvement, respiratory chain enzyme activity and
mtDNA copy number have been normal in muscle and decreased only
in liver tissue. For example, many patients with autosomal recessive
mutations in the POLG gene causing Alpers syndrome (intractable
epilepsy, hepatopathy) have normal respiratory chain enzyme activity
Figure 3 PicoGreen staining of fibroblast cultures. Healthy control fibroblasts exhibit typical bright punctate nucleoid staining when stained with the
fluorescent DNA dye PicoGreen (a). Co-staining these cells with the potential sensitive mitochondrial stain, TMRM demonstrated a normal polarized
mitochondrial network in all cells (b). Fibroblasts from patient 3 mostly exhibit typical bright nucleoids staining, but some cells (arrow) lack puncta (green
in on-line version) because they are depleted of mtDNA, termed mosaic mtDNA depletion (c). Co-staining of these cells with TMRM demonstrates that some
of the mtDNA-depleted cells have a depolarized mitochondrial network (d). Fibroblasts grown from patient 17 umbilical cord also show mosaic mtDNA
depletion (e), most cells having normal TMRM signal (f) but one depolarized cell is shown (arrow) consistent with mosaic mtDNA depletion. Scale
bars¼50mm.
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and mtDNA copy number in skeletal muscle.20,26 The characterization
of tissues from previously described patients with MPV17 mutations
has revealed a severe mtDNA depletion that was most pronounced in
liver, followed by a less severe, but still significant depletion in skeletal
muscle.6,15 In our cohort, respiratory chain analysis in muscle revealed
a combined deficiency of respiratory chain complexes in four out of
seven muscle biopsy samples available for biochemical studies, and
mtDNA depletion was identified in three out of eight muscle samples
with borderline low copy number in two samples. Therefore, muscle
from three out of eight patients showed no evidence of mtDNA
depletion. Interestingly, there was no clear correlation between the
level of mtDNA depletion in muscle, disease severity or mutation
location.
As predicted, respiratory chain enzyme activities and mtDNA copy
number in liver tissue correlated more closely with disease severity.
Liver was available for mtDNA copy number analysis in seven
patients. Severe mtDNA depletion in liver (o20% compared with
age-matched controls) was associated with early onset and severe
disease course (Table 1). In addition, when measured in both tissues
(five patients), the mtDNA content was significantly less in the liver
than in the muscle (P¼ 0.04, one-tailed paired sample T-test). Both
of these features are also apparent in patients with Alpers syndrome
due to POLG mutations.20 Although liver respiratory chain enzyme
activities or histochemistry were only available for three patients, this
also showed some correlation with disease severity, as the only sample
with normal activity was from patient 4 with the mildest disease.
PicoGreen stainings of fibroblasts
We identified mosaic mtDNA depletion in fibroblasts by PicoGreen
staining in three cases (patients 3, 11 and 15) with an early-onset liver
disease (birth–2.5 months), two of whom had severe mtDNA
depletion in liver (5% in patient 3 and 11% in patient 11); fibroblasts
grown from the umbilical cord of patient 17 (now 5 months old and
deteriorating rapidly with liver failure, and whose older sibling,
patient 16, was severely affected and had severe liver mtDNA
depletion) also showed mosaic mtDNA depletion. In four other
patients (2, 4, 8 and 9) from whom fibroblasts were available, there
was no clear evidence of mosaic mtDNA depletion even after
extensive passaging, and these patients had more variable onset
(birth–5 years) and mtDNA copy number in liver (14–40% of
controls). Muscle mtDNA copy number was highly variable both in
patients with mosaic mtDNA depletion (25–100% of controls) and in
patients without mosaic mtDNA depletion (46–80% of controls).
Thus, mosaic mtDNA depletion was more apparent in patients with
severe clinical phenotype and low mtDNA content in liver, but did
not appear to correlate with muscle mtDNA content. A similar
association between the cellular phenotype and severity of the clinical
phenotype has previously been seen in patients with the most severe
POLG mutations.20,23 Mosaic mtDNA depletion has also been
detected in serum-deprived mouse embryonic fibroblasts lacking
MPV17 protein, using antiDNA antibodies,3 but has not previously
been observed in patients with MPV17 mutations. Finding mosaic
depletion in fibroblasts, post mortem may provide a useful clue to
aetiology in cases where fibroblasts are the only material available for
diagnosis.27
CONCLUSION
Our data confirm previous reports describingMPV17mutations as an
important cause of mtDNA maintenance disorders, specifically
hepatocerebral MDS. We describe 17 patients with 11 novel MPV17
mutations and provide the first description of recessive MPV17
mutations associated with mosaic mtDNA depletion in fibroblasts.
We present evidence that MPV17 mutations lead to tissue selective
impairment of mtDNA replication and to a mosaic defect pattern in
fibroblasts, which is associated at least in some patients with the
severity of clinical phenotype.
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